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ABSTRACT 
Pulmonary drug administration has been the subject of investigation due to its advantages 
such as the avoidance of the first pass effect, rapid onset of action and small drug doses. 
Carrier-based dry powder inhalers (DPI) are, as the name indicates, dry powder formulations 
of inhaled medications. In these, the micronized active pharmaceutical ingredient (API) is 
blended with coarser excipient particles, the carrier, to provide better bulk properties, flowability 
and achieve reproducible dosing. However, the production of DPI products is quite complex 
and to obtain stable formulations, particle properties of the API, excipients and their respective 
mixtures are important factors to consider. The aim of this work was to understand how the 
mechanical properties of distinct powder particles intended for inhalation, influence the powder 
bulk properties and, consequently, their influence in the in vitro aerodynamic performance of 
DPIs. For this, jet-milled Salbutamol Sulphate (SS) was selected as a model API and four 
different grades of lactose (Duralac  H, Flowlac  90, Respitose  SV003 and Lactohale  100) 
were chosen as potential carriers. Adhesive blends of API (2%) and excipients were produced. 
Particle size distribution (PSD), hardness, porosity and flowability of the powders and blends 
were studied. It was found that the API increased the values of tensile strength of pure lactoses 
due to a decrease in porosity. Also, it was demonstrated that cohesivity and compressibility of 
the powder bed of the raw materials and blends increased with the presence of a higher 
percentage of fine particles. However, the latter turned the powders less permeable to air. 
Finally, the aerodynamic performance of the adhesive blends was tested using a Next 
Generation Impactor (NGI), at two different flow-rates: 60 and 100 L/min. It turned out that a 
higher flow-rate resulted in a higher fine particle fraction (FPF) values for all the blends. The 
best performance was achieved with SS+Duralac  H, being unresponsive to different flow-
rates and having the highest and constant values of FPF. 
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1. INTRODUCTION 
Pulmonary route can be used to deliver drug substances in form of aerosols or vapours into 
the lungs, for a systemic or local therapeutic effect1,2. Through this method of delivery, it is 
possible to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease 
(COPD) and cystic fibrosis1. When compared with other routes of administration, delivery to 
the lungs has some significant advantages, such as the reduced risk of systemic adverse side 
effects, a rapid onset activity, the ability of administering smaller doses locally (compared to 
the oral or parenteral delivery) and finally the circumvention of the first pass effect, bypassing 
the metabolism in the liver1 4. In fact, due to its large surface area available for absorption 
(~100 m2), with a thin absorption membrane (0.1-0.2  L/min), 
the lungs can also be used to distribute the active pharmaceutical ingredient (API) through the 
whole body4. Notwithstanding, pulmonary administration can be very complex and several 
aspects should be taken into account when developing new orally inhaled products (OIPs), i.e. 
the type of inhaler, the dry powder inhaler (DPI) formulation and the 
condition5. As a result, understanding the structure and function of the human respiratory tract 
and its relationship with the product characteristics are key aspects in the development of new 
inhalation therapies. 
 
1.1. Respiratory Tract 
The respiratory tract is divided in two parts, the upper and the lower part. The upper part is 
formed by the mouth, oropharynx, larynx and glottis and the lower part consists in the trachea, 
primary bronchi, bronchioles and alveolar ducts ending up in the alveolar sacs (Figure 1). 
These alveolar sacs contain bundles of alveoli surrounded by blood vessels, between which 
the unrestricted gas exchange occurs, guaranteeing blood oxygenation5. The respiratory 
system is divided 23 times, forming a branched system and after each bifurcation, two new 
airways arise, duplicating the airways after each branching. For this reason, after each 
bifurcation, the cross-sectional area of each subsequent airway decreases and the cross-
sectional area of all airways increases, decelerating the airflow and changing the pattern flow 
from turbulent in the trachea to laminar in the alveoli, reducing the airflow resistance inside the 
airways6. 
 
 
 
 
 
 
 
Figure 1  Schematic representation of the respiratory tract 
(from 5) 
 
1.2. Deposition of Inhaled Particles 
Particles are considered deposited in the respiratory tract when they are definitely removed 
from the flow streamline. For this reason, it is very important to understand the process and 
the factors that influence particles settlement in the surface of certain regions of the airway 
tree. Thus, the deposition of inhaled particles can be determined by the airway geometry, 
airflow velocity and particle shape. API particle size and its respective distribution are the 
parameters that are considered more often when engineering particles for pulmonary drug 
delivery7. In order to achieve its therapeutic targets within the lung, it is generally agreed that 
particles have to be in an aerodynamic size range of 1-5  will 
impact in the throat and do not go into the lungs8 10. 
The aerodynamic diameter of a particle is defined as the diameter of a sphere with a density 
 that settles in a motionless air with constant velocity as the considered particle 
(Equation 1): 
 (1) 
where d is the diameter of the sphere,  is the spherical particle density and 0 is unit density. 
For non-spherical particles, the particle shape also influences the aerodynamic diameter and, 
for that reason, a shape factor may also be applied to the equation ( )7. Considering that 
particles designed for inhalation have often different sizes, the mass median aerodynamic 
diameter (MMAD) and its geometric standard deviation (GSD) can be used to describe the 
particle size distribution (PSD). MMAD corresponds to the diameter of a particle where 50% of 
the total aerosol mass has a smaller particle diameter and the other 50% has a larger particle 
diameter. The GSD indicates the magnitude of dispersity from the MMAD value7. 
 Particle deposition can occur via three different mechanisms: inertial impaction, 
sedimentation due to gravity and diffusion (Brownian motion)5,7,8. When the particles diameter 
is larger than 5 as small as 2 , inertial impaction is the most relevant mechanism. 
Particles that deposit through this mechanism are not able to follow the trajectory of the 
surrounding fluid (air), depositing usually in the upper airways down to the primary 
bronchi7,11,12. Sedimentation is the settling of a particle caused by the force of gravity and its 
density difference in relation to the surrounding fluid, affect aerosols in the size range of 0.5-5 
; these particles settle and deposit on the lower surface of an airway11,12. At last, particles 
smaller than 0.5 ainly deposited due to diffusion. In this case, particles are strongly 
exposed to collisions with the surrounding gas molecules and exhibit a random movement 
(Brownian motion). These particles mostly deposit in the alveoli where the velocity of the air is 
very small7,11,12. 
 
1.3. Inhalation Devices 
The efficiency of pulmonary drug delivery is highly dependent on the device chosen. For 
the development of an inhaler it is important to take into account several factors, such as the 
type of drugs used, the physicochemical properties of the drug substance (solubility profile, 
particle size, morphology and density), the type of formulation (dry powder, propellant driven 
liquid or aqueous inhalation formulation) and the design of the device for both compatibility 
with the formulation and suitability for the targeted patient population13. A good inhaler, among 
some other characteristics, should be easy to use, easy to carry and of equal ease of usage 
in patients with different physical performances9,14,15. 
There are three main types of devices for pulmonary drug delivery: pressurized metered-
dose inhalers (pMDIs), nebulizers and DPIs1,13. These devices use different approaches to 
deliver the drug to the lung and they vary in both dosing principle and type of formulation. 
pMDIs are composed of formulations where the APIs are either dissolved or dispersed in a 
propellant and, through the actuation by the patient, the liquid phase is nebulized into  inhalable 
particles16. In nebulizers, a suspension or an aqueous solution containing API is nebulized, 
too. However, they are used as stationary devices and hardly ever as portable ones13. Finally, 
as the name indicates, DPIs allow the delivery of a dry powder of the active drug to the lung9,10.  
 
1.3.1. Dry Powder Inhalers 
DPIs are devices made up of three different parts. Each part contributes to the aerodynamic 
performance and hence to the efficiency of pulmonary drug delivery; namely, these are: the 
formulation, the dosing/container system and the device with the powder de-agglomeration 
unit and mouthpiece8. 
There are different categories of DPIs, based in their dose type (Figure 2), i.e.: Single dose, 
where a capsule or a blister is filled with a metered powder that contains the API and multi 
dose, where a formulation is stored in a reservoir container and metered upon activation. In a 
single-unit dose device, the drug is formulated as a micronized drug powder and carrier 
system, being inside an individual gelatine capsule, which are is inserted into the inhaler and 
discarded after use. Concerning the two different multi-dose devices, the multi-dose reservoir 
stores the formulation in bulk and has a mechanism which allows the inhaler to meter individual 
doses from the bulk upon inhalation; the multi-unit dose device uses factory metered and 
sealed doses packaged in a manner that the device can hold multiple doses without having to 
reload, which is an advantage since the formulation is protected from the environment until 
use, ensuring adequate control of dose uniformity17.  
These types can be summarized as passive devices or breath-actuated devices, which 
trigger powder release by the inhalation of the patient. The pulmonary drug delivery with these 
devices depends on the respirable flow-rate achieved by the patient9,14,15,18. On the other hand, 
there are active DPIs which use integrated facilities such as electrically operated impellors to 
prompt powder dispersion16. 
The first DPIs on the market were the single dose ones (Figure 3) and these are still in use 
nowadays. In these, the capsule or blister, which is used just for one application, is pierced by 
the inhaler device and then, via a deep breath of the patient, the powder is released and 
delivered into the lungs16. An example of a single dose DPI is Pharmachemie Cyclohaler .To 
overcome the need of refilling the DPI after each use, multi dose DPIs were developed. In 
these, the powder is filled into an attached reservoir or be contained in multi-unit doses from 
which metered single doses are administered to the patient19. It is important to note that the 
dose metering system must deliver a consistent amount of the formulation into the airstream. 
The former depends on the weighing of the container and/or the effective discharge of the 
compartment during inhalation20. 
The several DPIs can lead to clinically relevant variations in the performance between the 
different existing devices. Therefore, these must be considered when prescribing a specific 
device to a certain patient. For example, the inconvenient and complex procedure of loading 
single-unit dose devices has been associated with a high age related error rate17. 
Recently, Hovione launched a single used disposable inhaler which has been accepted 
worldwide, called TwinCaps . This inhaler can deliver lactose-based or particle-engineered 
powders and has the capacity to deliver large drug doses. It has been approved in Japan for 
the delivery of Inavir , a long-acting neuraminidase inhibitor for the treatment of influenza. 
TwinCaps  has high efficiency, it is a market-leader in Japan and it is entering in USA. Also, it 
has the lowest number of parts on the market (2 parts) for highest manufacturability in the 
industry, no metal parts, blades or springs and it is under patent until 202721. 
 
Figure 2  Types of DPIs and illustrations of four dosing design options available. 
single-unit dose, single-use disposable, multi-unit dose, multi-dose reservoir 
(adapted from 17,22) 
 
 
Figure 3  Capsule-based DPI: one single dose DPI 
(from 23) 
 
The main difficulty associated with inhalation drug powders and their efficient delivery is the 
strong interparticle forces which turns the cohesive bulk powder agglomerate. There are three 
different types of interparticle forces, namely Van der Waals force, which becomes noticeable 
when particles are close to each other (0.2-
less), capillary force and electrostatic force. The addition of external energy or reduction of 
surface force of particles may lower those interparticle forces, since they may alter surface e 
morphology or surface chemistry. Being that, there are different formulation strategies in DPIs, 
for example, carrier free, spherical pellets and adhesive mixtures8,20. There are some 
considerable differences between those formulation principles, such as: 
Carrier free systems: 
 API particles are engineered in a way that allows drug aerosolization without the aid 
of large excipient particulates; 
 Some properties of API particles must be altered and controlled, such as surface 
roughness (corrugation), particle size, density and shape; 
  API particles must be produced using spay drying, super-critical fluid processing 
and sonocrystallization. 
Spherical pellets: 
 Spheronized agglomerates of small drug particles which are sieved to obtain easy 
dispersible pellets with 200-2000 ; 
 More appropriate for high dose drugs (mg range). 
Adhesive mixtures: 
 Carrier-based formulations, where the fine API particles are mixed with a coarser 
carrier -lactose monohydrate crystals, since these are approved 
and generally accepted as safe by most regulatory agencies8,17,22.  
 
Carrier-based formulations present advantages, such as increasing the bulk of formulation 
and improving flowability of the small cohesive drug particles. The former allows easier 
metering of small quantities (usually < 100 improving dosing consistency. 
The latter improves processing of the formulation (e.g. flow characteristics, avoidance of 
segregation) during manufacturing and aerosolization during DPI22. 
 
1.4. DPI Formulation 
1.4.1. Particle Engineering 
There are several methods to engineer particles. These include spherical crystallization, 
mechanical milling (jet-milling), spray drying, precipitation and other several techniques24. 
Each of them produces particles with unique physicochemical characteristics that can further 
affect processing and inhalation performance8. 
The major aim of particle engineering is to improve some characteristics of the powders, 
taking into account the specifications of the inhaler device that will be used, as well as the 
intended type of drug delivery25. Particles engineered by different methods have different 
characteristics. For that reason, solid particles for pulmonary delivery will exhibit different 
aerosolization behaviours depending on the nature of the interparticulate interactions, type of 
formulation, inhalation device, flow-rate and breathing pattern25. 
Several techniques have been described in carrier engineering, for example spray-drying, 
which has been used to produce spherical particles with different surface topographies 
depending on the process  parameters. Moreover, lactose has been extensively engineered 
using techniques such as mechanofusion, that results in particles with very smooth surface or 
spherical crystallization, leading to spherical aggregates of lactose particles25.  
Nowadays, milling is the most common technique to obtain particles between 1-5 
range (respirable sizes) and there are several milling methods well established and validated 
available26, namely vibration milling, ball milling and jet-milling (fluid energy)25. Pressure, 
friction, attrition, impact or shear lead to the particle size reduction25. This process can disrupt 
the crystalline phase leading to the production of random domains of various molecular 
disorders, specially amorphous ones27,28.  
Air-jet milling (Figure 4) is the technique used to manufacture inhalation products, which 
causes particle acceleration, impact, self-attrition, fracture and consequent size reduction27. In 
this technique, particles are carried on a high velocity gas stream (usually with air or nitrogen) 
into an opposing high velocity gas stream such that particles impinge on each other and the 
walls of the mill shattering ultimately into respirable sizes. These particles are, then, collected 
by elutriation29. 
 
Figure 4  Schematics of an air-jet mill: (a) front view, showing the opposite high velocity gas 
stream inside the mill and (b) side view, showing the filter and the collection vessel separated 
by the cyclone behind the mill 
(from 29) 
 
 
 
 
1.4.2. Particle Properties 
The physicochemical properties of the carrier and drug may have a strong impact on further 
processing and on the aerodynamic performance of the formulation. To be able to produce 
potent adhesive mixtures, it is necessary to analyse and understand the influence of particle 
properties, since they affect cohesive and adhesive interactions. It is important to say that 
adhesive forces act between particles with different properties and cohesive forces among 
particles with similar properties30. These properties include solid-state of the material, particle 
micromeritics and surface morphology31. 
 
1.4.2.1. Solid-State 
To obtain outstanding efficiency of aerosols, it is necessary to develop an optimized 
formulation and, for that, the solid-state of the powders (chemical and physical stability) must 
be well known. Usually, the particles can be either crystalline or amorphous25. 
The crystalline form is typically described by polymorphs and pseudopolymorphs. 
Polymorphism is a phenomenon in which crystals display different lattice structures or 
molecular conformations without changing its chemical composition. Pseudopolymorphs are 
crystalline solvates and hydrates, which bound organic solvents or water molecules, 
respectively, to the crystal structure itself32. Amorphous solids usually have a higher dissolution 
rate and solubility; nevertheless, they present a higher Gibbs free energy, which means they 
are less stable chemically and physically. For that reason, they can recrystallize, changing the 
surface characteristics of the powder33. 
During secondary processing (particle engineering), amorphous regions can appear in 
crystalline materials and this phenomenon called mechanical activation can be beneficial in 
specific cases and it is usually dominant on the surface34,35. Also, reactivity, conductivity, 
surface free energy and true density are influenced by mechanical activation and these 
variations might influence the performance of inhalation products34. 
There are several methods to characterize solid-state, such as small and wide-angle X-ray 
scattering (SWAXS), Fourier transform infrared spectroscopy (FTIR) and differential scanning 
calorimetry (DSC). In most techniques, the detection limit for quantification of amorphous 
content is between 5 to 10%, which sometimes can be a problem especially when small 
amorphous content are on the surface of the powder36. 
 
1.4.2.2. Micromeritics 
Particle Size 
Concerning DPI formulations, drug particle size is of extreme importance to assure that 
drug particles can penetrate the small airways. 
According to Kulvanich et.al.37, adhesion forces increase with the decreasing of the particle 
size. When the size range is below 10 , adhesion forces exceed gravitational forces and 
particles become able to adhere to larger ones. These fine particles are highly sticky, cohesive 
and have poor flowability because of the dominant attraction force38. Thus, it is expected that 
the API particle detachment during inhalation improves with the decrease of mean drug particle 
diameter. However, this detachment does not exclusively depends on the attraction forces, but 
on the magnitude of the removal forces as well and it was observed that increasing the drug 
particle size enhance particle aerosolization39. For this reason, and because the particles of a 
powder are heterodisperse (different particle sizes are present), it is very important to 
determine the powder PSD.  
The PSD of a powder can be represented by a cumulative or density curve based on 
number (q0, Q0), length (q1, Q1), area (q2, Q2) or mass/volume (q3, Q3), which can be used 
to determine a mean particle size (Dv0.5) and MMAD38. In terms of aerosol quality and 
efficiency, PSD is a key parameter and is commonly evaluated by the determination of the 
polydispersibility (PDI), which is usually known as Span value (Equation 2). A higher value of 
PDI of the carrier indicates a wider PSD, leading to a more heterogeneous blend and can lead 
to a higher variability in lung deposition of drug upon inhalation40. 
    (2) 
Several techniques can be used to measure the PSD, such as sieve analysis, light 
scattering and laser diffraction, image analysis, etc., the most common one being laser 
diffraction. 
Light-scattering methods (Figure 5) are a commonplace in formulation development26. 
Laser diffraction involves the measurement of a representative sample, dispersed at an 
adequate concentration in a suitable liquid or gas. For the measurement, the powder should 
pass through an expanded laser beam. The light of the laser beam is diffracted in different 
directions, according to the different particle sizes, and the scatter pattern is recorded by 
detectors. The scatter pattern is related to the particle size and its distribution. The laser 
diffraction results are often expressed as a volume distribution. The full profile is evaluated, 
and particle size is generally specified as a three-point specification containing Dv0.1, Dv0.5 and 
Dv0.9 value. The percentage of fine particles below 5, 10 or 15 can also be determined. 
These parameters can potentially be linked to the product performance26,41. 
The distribution of scattered light is a 
of the particle and the dimensionless particle diameter42, as represented in Equations 3 and 4. 
    (3)      (4) 
The algorithms are based on Fraunhofer or Mie theories, from which the particle sizes are 
determined. Since the algorithms differ among the different instruments, comparison is difficult, 
particularly for the majority of pharmaceutical particles, which deviate from sphericity26. The 
 > 10) and the theory of Mie 
can be used for relatively small particles (0,1 <  < 10)42. 
The scattering pattern of small particles is extremely complex, such that the direct 
calculation of a particle diameter is impossible. For that reason, calibration with defined 
particles is used. For a reliable calculation of the particle diameter, multiple detectors are used. 
Two examples of laser equipment are Sympatec and Malvern. 
 
 
Figure 5  Schematic representation of a laser-light scattering method, showing how the 
laser beam passes through the powder and the laser diffract in different directions according 
to different particle sizes 
(from 26) 
 
Also, fine particles have an important role in the aerodynamic performance of DPIs. The 
particle size compared to coarse ones. In this thesis, particles smaller than 10 
 Although the numerous studies developed in how fines may affect 
the performance of DPI formulations, the results are contradictory. Some studies showed that 
small quantities of fines could increase the deaggregation efficiency and lead to a therapeutical 
efficacy of the DPI. However, some other studies proved that fines would decrease the 
deposition of the powder in the lung, decreasing the fine particle fraction (FPF) value40. Several 
theories exist about the role of the fine particles in DPI performance40,43: 
(a) Active-sites theory: active-sites are defined as areas on the carrier surface that are more 
adhesive than others, which are preferentially occupied by fines. However, there were 
some criticisms to this idea, since it cannot explain how active sites affect the 
performance of a powder for inhalation; 
(b) Fluidization theory: fluidization of a DPI occurs when the pressure drop across the 
powder bed (PD) is equivalent to the weight of the powder. So, the addition of fines 
improves DPI performance by increasing the tensile strength (TS) of the formulations, 
which is related to the interparticulate forces and the free volume of the carrier; 
(c) Agglomeration theory: the presence of fines results from the formation of drug-fine 
agglomerates and these are easier to remove from the carrier surface than API particles 
due to the greater aerodynamic drag force that exists on agglomerates; 
(d) Buffer hypothesis: usually, commer -lactose monohydrate has a rough surface and 
carries natural fines and impurities on its surface, which may influence their interaction 
with the drug. Dickhoff et. al.44 developed a study where lactose was submerged in 
ethanol-water mixtures and it was found that submersion removed the adhering lactose 
fines, leading to a decrease in drug particle detachment without affecting shape or size 
of the carrier. Adhering lactose fines act as a buffer between colliding carrier particles 
and protect smaller drug particles attached to the same crystal planes from the press-
on forces that cause increased drug particle detachment during inhalation; 
(e) Case-dependent theory: Fines do not always improve the aerosol performance of a DPI, 
which is determined by the formulation and dispersion conditions. According to the study 
developed by Grasmeijer et. al.45, the presence of coarse lactose fines (CLF) led to a 
higher detachment of the drug at all flow-rates. To explain these results, two 
mechanisms are involved: first, fines below a certain size reduce the dispersion 
performance, increasing the effectiveness of press-on forces; second, lowering TS, CLF 
may weaken or prevent the formulation of fine particles network. 
 
Particle Shape 
The shape of the particle must be considered when developing a DPI formulation. Particle 
shape is one of the most intractable and uncontrollable factors in powder technology, being 
important to analyse the influence of this property, since different shapes, such as spherical, 
tomahawk or irregular, lead to different results. It is known that higher contact areas and shorter 
interparticulate distances, lead to stronger adhesion forces38. Irregular shaped drug particles 
are usually more cohesive/adhesive than spherical particles46. Furthermore, particle shape 
also has a great impact on the flow behaviour of dispersed particles: elongated particles are 
very aerodynamic, resulting in a smaller aerodynamic diameter compared to spherical ones, 
but they tend to have a poorer flowability. Therefore, elongated particles disperse better in a 
gas stream and penetrate further in a branching system, as is the case of the lungs38. On the 
other hand, spherical particles with low density tend to bind the API for a longer period, 
reducing the drug loss at different flow-rates and thus enhance the drug delivery40. 
Scanning electron microscopy (SEM) is an example of a method that allows the 
determination of the shape and morphology of a particle. Also, contact angle measurements 
 and optical microscopy are used to determine the particle shape 
of the powder. 
 
Surface Morphology 
Surface area is not exclusively determined by particle size and shape, but also by the 
morphology of the particle. The morphology of the particle surface determines the contact area 
between drug and carrier particles and the magnitude of adhesion forces38. Rough particles 
have more surface area than smooth ones. Thus, particle morphology can also be engineered 
for DPI formulation design26,47. Carrier surface is formed by active sites in which fine drug 
particles primarily and strongly adhere to. These active sites can have several sources, such 
as impurities, surface asperities and crystal lattice defects48. There is the possibility to create 
drug particles with specific morphology or select particles to obtain specific surface 
morphologies and the interparticulate forces can be modulated to enhance lung deposition. 
Ideally, the contact area and, consequently, the forces should be adjusted to a level that offers 
enough adhesion between drug and carrier to provide a stable formulation yet allowing easy 
separation upon inhalation26. 
As mentioned previously, SEM can be used to determine the surface morphology. SEM 
scans a sample with a focused electron beam over a surface and deliver images with 
 (Figure 6)49. The electrons interact 
with atoms present in the sample, which produces signals containing information about the 
surface topology and composition of the sample. The electron beam is scanned in a raster 
scan pattern and the position of the beam is combined with the detected signal to produce an 
image. It is used to study the morphology of the particle, giving information about the 
roughness or smoothness of the particle itself50. 
 
Figure 6  Schematic representation of the working principle of a scanning electron 
microscope 
(from 51) 
1.4.3. Bulk Formulation Properties (Adhesive Mixtures) 
It is known that different engineering techniques lead to different solid structures and, 
consequently, different solid-state behaviours, micromeritics and surface morphologies, 
influencing particle interaction. The surface energy of a material is the necessary energy to 
increase the surface area of a solid particle. Therefore, particles with different solid-state 
properties, micromeritics and surface morphologies will exhibit different surface energies38. For 
instance, it is known that molecular disordered spots that exhibit higher surface energies can 
be induced on the surface of the milled particles, resulting in an increased particle 
cohesiveness and adhesiveness52. Drug particles with higher surface energies adhere better 
to the carrier surfaces53. Also, the water uptake of the particles depends on the differences in 
solid surface structures. When the surface structure is amorphous, the absorption of water is 
higher, leading , potentially impacting on product 
performance. 
Two different forces act during a mixing process, which are the cohesive forces between 
the drug particles and adhesive forces between the API and the carrier particles. To complete 
the mixing process and avoid the agglomeration of the particles, the adhesion force must be 
high enough. However, the redispersion of the drug affects the performance of the DPI, which 
is influenced by three factors: the inhaler device, the inhaler manoeuvre of the patient and the 
formulation. These factors determine the FPF which is the part of the API supposed to reach 
the deeper part of the lungs54. Usually redispersion is easier for smaller carrier particles and 
the particle surface roughness is a main factor when considering adhesion and friction. In the 
resuspension process, the particle shape is important for the adhered drug particles, but the 
shape of the carrier particles might influence the mixing force. During mixing, occurs the friction 
between the particles of the powder. Friction is smaller for spherical and smooth particles and 
increases with the increase of the irregularities in the particle shape, increasing interparticle 
forces. The latter will cause a change in the resuspension properties of the interactive powder 
mixture55. 
Carrier rugosity and active carrier sites are two important factors for the performance of a 
DPI. Those can be manipulated by adding fines to the carrier material or other materials56,57. 
Manipulation of the carrier material causes changes in the adhesion forces between carrier 
and API. The adhesion force should not be too high so that the detachment of the drug particles 
during inhalation is possible and to avoid the impaction of the API together with the carrier in 
the upper airways. Thus, the adhesion force is a key parameter for the behaviour of the 
interactive mixture54. 
 
1.4.3.1. Flowability 
The behaviour of the powder bulk depends on several factors, including the particle 
properties already mentioned before (particle size, PSD, shape and surface roughness). 
Besides those factors, flowability, compressibility, dispersibility and fluidization are important 
to have into account, as well. For example, spherical particles have a higher flowability when 
compared with irregular particles, due to less interparticle contact points31,58. Powder mixtures 
can be more or less cohesive and this promotes or reduces the aerodynamic performance, 
respectively31. For this reason, it is important to investigate the behaviour of a powder to draw 
a conclusion regarding the powder performance during mixing, dosing and aerosolization31,58. 
To analyse the powder bulk, usually a powder rheometer is used, for example, the FT4 
equipment (freeman Technology, Tewkesbury, UK). 
The powder bulk properties of an adhesive mixture for DPIs depend on the carrier. Poor 
carrier flowability and low carrier bulk density affects negatively  the mixing homogeneity and 
facilitates segregation31. The concentration of the drug at which the powder starts forming 
particle layers will depend on the interactive capability between the drug particles and carrier 
and it will influence the bulk of an adhesive mixture. So, if the ratio drug-carrier is high enough, 
it may result in a multilayer formation of adherent drug particles, even before the carrier surface 
is covered with a complete monolayer37. Also, it is possible that a complete saturation of the 
carrier surface occurs, resulting in free drug particles (not coupled to the carrier) that 
agglomerate59. Thus, it is advisable that the concentration of drug is adjusted to the 
physicochemical properties of the carrier, guaranteeing that all drug particles adhere to the 
carrier surface. 
As said before, fine particles are cohesive and have less flowability in contrast to coarse 
ones. However, it is important that the final formulation has enough flowability to obtain a 
reproducible dosing during the dispersion from the DPI device. This can be achieved by one 
of two ways: by controlling the aggregation of particles, forming loosely adherent floccules that 
improve dispersion or by using carrier-based formulations60. The last one has turned out as a 
challenge, since interactions between the drug and the carrier have an important influence on 
DPIs performance. Forces acting between carrier and API must be well balanced to guarantee 
detachment during inhalation.  
 
1.4.3.2. Aerodynamic Performance 
After developing a new DPI formulation, in vitro aerosolization performance should be 
tested. These in vitro tests allow to determine the possible in vivo action of the formulation, 
simulating the aerosol deposition inside the human lung. Impingers and impactors are two 
procedures used for testing the in vitro performance. The difference between an impinger and 
an impactor is the medium in which particles deposit: the impingers use liquid impaction plates 
and impactors use dry ones. However, it is possible to find a similar set-up in both devices; the 
, then succeeded by impactor plates (usually four 
to eight plates) with a filter at the end, where non-deposited particles are collected. There is a 
vacuum pump that creates an airflow through the plates, as well61. 
There are several types of impactors, but the most used one is the Next Generation 
Impactor (NGI) (Figure 7). The NGI has a horizontal setup with three main parts: the cut tray, 
the frame that holds the cup tray and the cover with the fixed nozzles and the inter-stage 
pathways. It contains seven impaction stages and a micro-orifice collector that acts as a filter 
and is responsible for collecting the finest fraction. The air enters the impactor through a bent 
inlet tube adapted into a pre-separator, where the carrier particles are collected. The air 
streams zig zags from stage to stage, through nozzle diameters that decrease stepwise and 
the air velocity increases, leading to a decreasing particle cut-off diameter as impactor stages 
progress. Each of the stages has a specific cut-off size that can be calibrated62. When testing 
a DPI, the airflow-rate varies between 28 and 100 L/min. Although, it is possible to calculate 
the cut-off diameters for a specific flow-rate61 (Equation 5): 
    (5) 
where D50Qn is the cut-off diameter of the standardized flow-rate Qn (often 60L/min) and D50Q 
is the cut-off of the applied flow-rate Q. The variable n depends on the individual stage and 
varies from 0.54 at stage 1 to 0.67 at stage 7. For this reason, the higher the flow-rate, the 
smaller the cut-off diameters for the individual stages61. To have an adequate correlation 
between in vitro assessment and in vivo action of the DPI, the airflow-rate should correspond 
to a pressure drop of a 4kPa over the device, and a duration consistent with the withdrawal of 
4 L of air should be employed61.  
 
 
 
 
 
 
 
 
 
 
Figure 7  Representation of the NGI when (a) open, showing the nozzles and collection 
cups with the indication of the zig zag airstream from stage 1 to 8 and (b) closed, 
bended inlet tube and the pre-separator 
(from 62) 
 
DPI formulation in vitro assessment is based on inertial impaction of aerosols. Particles get 
fractionated according to their sizes and from this it is possible to determine the particle 
aerodynamic diameters. Aerosols are constituted by particles of different sizes that exhibit 
different energies, particle mass and velocity. Particles with large aerodynamic diameters and 
heavier ones have a high momentum, so they are not able to adjust fast enough when the air 
stream changes direction, impacting earlier than small particles that are transported further. 
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Consequently, the probable impaction of aerosols can be calculated using the particle Stokes 
number, which is a dimensionless parameter which governs the efficiency of particle impact 
on a collection plate (Equation 6): 
    (6) 
where U0 is the average fluid velocity to the nozzle,  is the particle density, d is the particle 
diameter, Cc is the Cunningham slip correction factor,  is the dynamic viscosity of air and Dn 
is the nozzle diameter. 
particles with a diameter of less than 1 
spherical, that their Re is less than 0.1 and that their density is greater than air density. The 
particle will impact on to a plate if its Stokes number is larger than 161. 
 
  
2. AIM OF THE THESIS (HYPOTHESIS) 
Particle properties such as PSD, shape and solid-state can influence interparticle 
interactions that in turn will influence powder bulk properties, i.e. flowability and in vitro 
aerodynamic performance.  
Therefore, the aims of this thesis were to understand how the particle properties affect the 
powder bulk and, consequently, how all these properties influence the aerodynamic 
performance of carrier-based DPIs and which particle property most influences the 
aerodynamic performance of carrier-based DPIs. Four different lactoses with distinct solid-
state, micromeritics and surface morphologies were chosen to be tested. Jet-milled Salbutamol 
Sulphate (SS) was used as model API and mixed with the carrier at a load of 2% (wt%). All the 
raw materials and resulting blends were analysed via PSD by pressure titration, breaking force 
and powder rheometry. Finally, the aerodynamic performance of the adhesive blends was 
determined by NGI, obtaining the aerodynamic particle size distribution (APSD) and the FPF.  
  
  
3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Solvents 
Purified water (TKA Wasseraufbereitunssystem GmbH, Germany), acetic acid (Emprove, 
Merck Millipore, USA) and isopropanol (VWR Chemicals, Germany). 
 
3.1.2. Raw materials: Carriers and API 
Micronized SS (Fagron GmbH & Co., Germany) with a particle size of Dv0.1  
0.5  0.9  Duralac  H 
(16%  anomer and 83.5%  anomer, Meggle, G -lactose monohydrate Flowlac  90 
  3%, Meggle, Germany), Respitose  
Germany) and Lactohale  
carriers. These powders were chosen as potential carriers due to their distinct solid-states, 
particle shapes, as well as different values of specific surface area (SSA) (Table 1 and Figure 
8). 
 
Table 1  Characteristics of the potential carriers ( -sph, -tom_sm and -
tom_lar), namely solid-state properties, SSA (m2/g) and their morphology 
Raw material Sample name Solid-state SSA (m2/g) Morphology 
  
Anhydrous - and 
-lactose clusters 
0.51 Very irregular 
 -sph 
-lactose 
monohydrate 
0.29 
Spherical with 
irregular surface 
and deep pores 
 -tom_sm 
-lactose 
monohydrate 
0.15 
Relatively smooth 
small tomahawk 
particles 
 -tom_lar 
-lactose 
monohydrate 
0.13 
Relatively smooth 
large tomahawk 
particle 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8  SEM images of the (a) ; (b) -sph; (c) -tom_sm; (d) -tom_lar  
(at 228.7 m width and 500x magnification) 
 
3.2. Preparation and Characterization of the Blends 
3.2.1. Preparation of adhesive mixtures 
Lactose was dry sieved through sieves (Retsch GmbH, Germany) using a vibratory sieve 
shaker (Retsch AS200, Germany) to obtain a 20-9  particle size fraction. 
Adhesive mixtures of 2% jet-milled SS were prepared. 49 g of lactose and 1 g of API were 
weighed into a vessel using the sandwich method : the first 24 g of the carrier was weighed 
in the vessel followed by a layer of 1 g of the API and then the rest of the carrier was added. 
The vessels were blended in a Turbula blender TC2 (Willy A. Bachofen Maschinenfabrik, 
Muttenz, Switzerland) for 90 min at 62 rpm (criteria stablished based on 27,63). 4 blends were 
prepared, one for each lactose studied. 
 
3.2.2. Mixing Homogeneity 
Homogeneity of each mixture was determined by taking 10 samples of approximately 25 
mg and dissolved in 10 ml of purified water. Samples were taken from the top, centre, bottom 
and close to the walls of the vessel, ensuring the uniform sampling. For the analysis of the 
dissolved samples, the absorbance -VIS 
(a) (b) 
(c) (d) 
spectrophotometer UV-2700 (Shimadzu, Kyoto, Japan). The measurements were made in 
triplicate (n=3). 
 
3.3. Powder Characterization 
3.3.1. Particle Size Distribution 
PSD was evaluated using laser diffraction (HELOS/KR, Sympatec GmbH, Germany). The 
powder was placed on a vibrating chute (Vibri, Sympatec GmbH, Germany) and dispersed 
using a dry dispersing system (RODOS, Sympatec GmbH, Germany). A sampling time of 10 
s (12 s real time) was applied and measurement with an R2 (0.45-87.5 -
875 , triggered once an optical concentration (Copt) of 0.5% was reached. To evaluate the 
pressure at which the particles de-agglomerate, a pressure titration was applied. For this, the 
primary dispersion pressure was manually adjusted in 0.2 bar step in the range of 0.1-2.0 bar. 
Measurements were done in triplicate (n=3) at 0.1, 1.5 and 2.0 bar. Before each measurement, 
the dispersing system was cleaned using sand and a reference measurement was taken.  
Moreover, and in order to evaluate the un-agglomerate state of the samples, the powders 
were evaluated using wet-dispersion (CUVETTE, Sympatec GmbH, Germany). Isopropanol 
was chosen as the dispersant medium. 50 ml of the alcohol were added into a stationary 
cuvette and very small amounts of powder were added, step-wise to the solvent. The system 
was magnetic stirred (1000 rpm) in order to disperse the samples. Measurements were carried 
during 120 s, once a Copt above 0.5% was reached.  
Particle size cumulative volume and number distribution (cumulative (Q3) and density (q3) 
distribution and Q0/q0, respectively) were calculated and analysed using Windox 5 software 
(Sympatec GmbH, Germany). 
 
3.3.2. Hardness and Tensile Strength  
The hardness of the plugs of lactose, SS and blends were evaluated using a 3-in-1 
hardness, diameter and thickness testing instrument (PTB 311E, PharmaTest GmbH, 
Germany). For that, it was necessary to compress the powders with a hydraulic press, using a 
500 kg load. Measurements were done in quintupled (n=5) and the thickness of the plugs were 
. The plug is put on the surface of the testing instrument and the pressure is 
applied in the lateral area of the plug itself, as represented in Figure 9.  
 
Figure 9  Schematic representation of the equatorial tablet tensile strength test 
(From 64) 
The TS was calculated using the Equation 764: 
    (7) 
where D is the diameter of the plug and T is the thickness of the plug. 
 
3.3.3. Density and Porosity 
The density of the materials was tested using a gas pycnometer (AccuPyc II 1340 TEC, 
Micromeritrics). For this, it was necessary to compress the powders using a hydraulic press. 
In order to be used, the pycnometer had to be calibrated using three metal spheres and, for 
the actual measurement, five plugs were placed inside of its chamber. The equipment gives 
five values of volume that are used to calculate the density of the materials. Knowing the grain 
density of the plug and the bulk density, it was possible to calculate the porosity using the 
following formula (Equation 8)65: 
    (8) 
The values of the bulk density, which corresponds to the calculated density, were obtained 
dividing their mass (g) for the respective volume (cm3). The grain density of the plugs was 
directly obtained through the pycnometer.  
 
3.3.4. Dynamic Powder Flow Analysis 
To measure the flow properties of the samples, a FT4 Powder Rheometer (Freeman 
Technology, Welland, UK) was used.  
To measure the compressibility, a sample of powder was analysed using a 25 mm bore 
borosilicate glass cylinder. The samples were conditioned using a 23.5 mm blade which was 
moved down a helical path, allowing the displacement of the powder, which removes the 
packing history of the powder and any operator influence and, therefore, generates a 
homogenized uniform low packing stress in the powder. The cell was then split to remove any 
surplus powder. Formerly, the blade was replaced by a piston and a varying normal stress 
between 1 and 15 kPa was applied on the sample, obtaining eight values of compressibility at 
different pressures. Measurements were performed in triplicate (n=3). 
Powder permeability was measured using a 25 mm bore borosilicate glass cylinder. The 
samples were conditioned using a 23.5 mm blade which was moved down a helical path, 
displacing the powder. After conditioning the powder, the cell is split to remove any excess of 
powder. Permeability studies were conducted at a constant airflow velocity of 2mm.s-1, which 
was passed through the powder bed, with varying normal stress between 1 to 15 kPa being 
applied on to the sample, using a piston. Measurements were performed in triplicate (n=3). 
Powder cohesivity was analysed using a 25 mm bore borosilicate glass cylinder. Once 
again, the samples were conditioned using a 23.5 mm blade which was moved down a helical 
path, allowing the displacement of the powder. Then, the blade was replaced by a piston which 
compacted the sample. The cell was split to remove any surplus powder. At that point, the 
piston was substituted by a 24 mm sear cell and the test was carried out varying normal stress 
between 5 to 15 kPa being applied on the sample. Measurements were performed in triplicate 
(n=3). 
 
3.4. Aerosolization Assessment 
The aerosolization performance of the blends at both capsule fill settings was determined 
with a NGI (Copley Scientific, Nottingham, United Kingdom) and according to the procedure 
described in the US pharmacopoeia (Preparations for inhalation: aerodynamic assessment of 
fine particles, Ph. Eur., 7.0) and taken from the literature61. For the experiments, capsules were 
filled with, approximately, 40 mg of sample. At first, the vacuum pump (SCP5, Copley 
Scientific) was switched on and the small trays and the large cups were coated with a coating 
agent (2% solution of Tween 20 in absolute ethanol). The small impaction trays were coated 
with 2 ml and the two larger ones with 4 ml of the coating agent and 30 min were waited to 
guarantee that the coating agent was able to cure completely. The pre-separator was filled 
with 10 ml of acetic acid buffer (pH=3) and the flow-rate through the device was set to 60 and 
100 L/min using a critical flow controller (TPK, Copley Scientific), which was checked with a 
flow meter (DFM3, Copley Scientific). As an inhalation device, a unit dose DPI was selected: 
Cyclohaler . 
 
  
4. RESULTS AND DISCUSSION 
4.1. Particle Characterization of the Raw Materials and Blends 
To understand how the particle properties affect the powder bulk and, consequently, how 
all these properties influence the aerodynamic performance of carrier-based DPIs, some 
studies were conducted, such as PSD, hardness and porosity, compressibility, permeability 
and cohesivity. It is known that these parameters have a relationship between them and it was 
desirable to confirm these relations. However, the main goal of these analysis was to find out 
how they influence the aerodynamic performance of DPIs and, for that, an NGI analysis was 
made, which allowed to find which property most contribute to a better performance and, 
afterward, which lactose had the best characteristics to be an ideal carrier to be used in a DPI 
formulation. 
 
4.1.1. Blend Homogeneity 
To proceed with the study, it was necessary to analyse the mixing homogeneity, as 
described in section 3.2.2. According to US Pharmacopeia, blends are considered 
homogeneous when the relative standard deviation (RSD) is less than 5%. 
As represented in Table 2, all mixtures are considered homogeneous and, for that reason, 
the powder properties of the blends could be analysed. Since RSD are below 5%, it was 
possible to proceed with the research. 
 
Table 2  API content present in the blends and mixing homogeneity, in percentage, for 
- - -tom_lar 
Specification API content (wt%) Mixing Homogeneity  RSD (%) 
SS +  2.00 2.30 
SS + -sph 2.19 2.95 
SS + -tom_sm 2.20 3.84 
SS + -tom_lar 2.00 3.66 
 
4.1.2. Particle Size Distribution 
The laser diffraction system using wet and dry pressure titration was used to identify the 
presence or not of agglomerates and the respective force necessary to break them. Moreover, 
the PSD of the different materials was analysed and compared among each other using the 
volume distribution percentiles, i.e. Dv0.1, Dv0.5 and Dv0.9. Furthermore, the percentage of 
particles below 10 , considering the content of fine particles, was also evaluated. 
 
First, a dry dispersion measurement was performed. This type of measurement permits to 
overcome the binding forces between agglomerated particles, resulting in the optical dilution 
of the particle agglomerates, making them measurable by the sensor as individual specimens.  
The PSD values obtained at the primary pressures in the range from 0.1 bar to 2.0 bar are 
presented in Figure 10 and 11 for raw materials and blends, respectively. The particle 
diameters and Span values are in Table 3 and 4, which allows to understand if the raw material 
powders and respective blends were mono- or heterodisperse66. 
 
Table 3  Particle size volume distribution and respective Span of the jet-milled SS, -
-tom_sm and -tom_lar at primary dispersion pressure of 0.1, 1.5 and 2.0 bar 
Raw Material Dv0.1  Dv0.5  Dv0.9  Span* 
0.1 bar 
     
-sph     
LH -tom_sm     
-tom_lar     
SS     
1.5 bar 
     
-sph     
-tom_sm     
-tom_lar     
SS     
2.0 bar 
     
-sph     
-tom_sm     
-tom_lar     
SS     
*   (9) 
Triplicates were c  
 
 
 
 
Table 4  Particle size volume distribution and respective Span of the SS+ SS+ -sph, 
SS+ -tom_sm and SS+ -tom_lar at primary dispersion pressure of 0.1, 1.5 and 2.0 bar 
Raw Material Dv0.1  Dv0.5  Dv0.9  Span 
0.1 bar 
     
-sph     
-tom_sm     
-tom_lar    2 
1.5 bar 
     
-sph     
-tom_sm     
-tom_lar     
2.0 bar 
 2.84     
-sph     
-tom_sm     
-tom_lar     
 
 
By comparison of the mean particle size and its Span
lactose with larger distribution of particles, since it has the highest value of Span among the 
lactoses (Table 3). It is also visible that -sph has the lowest value of Span, which means it 
has a smaller distribution of particles. Moreover, in every primary pressure used, SS particles 
exhibit a Dv0.5 Span, which means that SS had the largest 
distribution of particles. 
Concerning the blends (Table 4)
distribution of particles, since it had the highest value of Span, which was concordant with the 
-sph had the lowest value of Span, having the 
smaller distribution of particles. Also, in general, it was possible to see that there was a 
decrease of the values of Dv0.1, Dv0.5 and Dv0.9 when compared with the raw material results, 
leading to higher values of Span, which is a natural consequence of adding 2% of fine SS 
particles to the raw coarser carriers.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10  Particle size density volume distribution at different pressure titrations from 0.1 to 
2.0 bar for (a) , (b) -sph, (c) -tom_sm, (d) -tom_lar and (e) SS  
Triplicates were carried out at 0.1, 1.5 and 2.0 bar (Mean  
 
 
 
 
 
(a) (b) 
(d) (c) 
(e) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11  Particle size density volume distribution at different pressure titrations from 0.1 to 
2.0 bar for (a) SS+ SS+ -sph, (c) SS+ -tom_sm, (d) SS+ -tom_lar 
Triplicates were carried out at 0.1, 1.5 and 2.0 bar (Mean  
 
According to the density distribution represented in Figure 10 - -
tom_sm have a mean particle size in the range 
smaller mean particle size of all the analysed carriers (Dv0.5 = , on average). 
-tom_lar presenting the largest particles, have a higher value of Dv0.5 (Dv0.5 = 
, on average). -lactose monohydrate has been 
employed as a carrier in adhesive blends and depending on the design of the DPI device, a 
67 is deemed as adequate, being also described 
that lactose carriers should be one order of magnitude greater than the drug particles (> 50 
68. Analysing the results in Figure 10 and Table 3, it is seen - -
tom_sm are within the mentioned range. Moreover, there are studies using capsule based 
DPIs that indicate that decreasing carrier particle size can lead to a better aerodynamic 
performance: studies that used polystyrene spheres wit  
(a) (b) 
(c) (d) 
showed exactly that. This result was attributed to the decreasing particle size, including 
decreased number of drug particles per carrier and the increase in particle number, surface 
area, intercarrier adhesion and number of collisions in the powder bed during 
aerosolization40,68. 
Regarding SS, it was apparent that at 0.1 bar the particles were agglomerated, which 
Figure 10(e)). However, when the 
dispersion pressure was increased to 0.3 bar, the Dv0.5  and no more 
. Moreover, when the pressure was 
further increased, this resulted in a plateau in the PSD, indicating that no more agglomerates 
were present. So, it is possible to say that primary particle 
which confirmed that the particles were appropriate to be delivered to the lungs8 10,27.  
Concerning the blends (Figure 11), SS+ SS+ -sph and SS+ -tom_sm have a Dv0.5 
, the same range encountered for the raw materials. Nevertheless, 
when a detailed analysis is done, all these blends have now a notable presence of particles 
allest Dv0.5 of all the 
when compared with the lactoses by themselves. This, as mentioned before, is happening 
because the lactoses were mixed with SS, which has a mean particle size . 
SS+ -tom_lar presented the largest particles, having a Dv0.5=
which is, of course, lower than the Dv0.5 of the raw material.  
Comparing the Span values obtained and the density distribution, it was conclusive that all 
the raw materials and blends have a heterodisperse distribution. Still, when analysing the 
blends, it is possible to detect a wider PSD, which is a consequence of a higher percentage of 
smaller particles present in the mixture67. Furthermore, it was seen that raw materials and 
blends presented a PSD between 2-  in accordance with the targeted gap to 
obtain a good DPI performance68.  
 
An important parameter to consider in the formulation of carrier-based DPIs is the 
percentage of fines within the blend (described in section 1.4.2.2.1). In this work, ines were 
considered all the particles in the sample which were smaller than 10  In Figure 12 are 
represented the distribution of the percentage of fine particles found in carriers, API and 
blends. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 12  Percentage of fine particles (smaller than 10 ) present in the samples at 
different pressure titrations from 0.1 to 2.0 bar for (a) carriers, (b) API and (c) blends 
Triplicates were carried out at 0.1, 1.5 and 2.0 bar (Mean  
(a) 
(b) 
(c) 
Figure 12(a) confirms that  is the lactose with the highest percentage of fine particles: on 
average, 15.0% of the particles were smaller than 10 . Of the remaining lactoses, it is seen 
that all of them have a reduced percentage of fine particles, where -sph had the lowest 
percentage of fine particles, around 0.86%. -tom_sm has 2.95% and -tom_lar 1.52% 
of particles smaller than 10 . The latter was expected considering -
 -tom_sm, as shown in SEM images (section 3.1.2.), Figure 10(d) and the values 
of Span in Table 3. 
As said before, a multimodal/heterodisperse carrier size distribution positively influences 
the performance of the drug. When a multimodal distribution is verified, it is expected that a 
higher percentage of fine particles are present in the powder68. A higher percentage of fine 
particles in carriers is imperative since it improves the DPI performance, and these are added 
n yet why 
and how the fine particles influence the DPI performance, existing several theories that try to 
explain this, as mentioned in section 1.4.2.2.1.67. According to Buttini et. al.61, a minor quantity 
of fine lactose particles can be used in order to promote deaggregation of the drug powder. 
Likewise, fine lactose particles will adhere on to the larger carrier particles, reducing drug-
carrier contact, facilitating drug dispersion and deposition, leading to a better aerosol 
performance. 
Regarding the API, Figure 12(b), it is possible to see that around 89.00% of the SS particles 
are smaller than 10 , which confirms that most of the particles in the jet-milled sample were 
fine ones. Also, when the sample was analysed under a pressure of 0.1 bar, the percentage 
of fine particles was considerably lower, since SS particles were agglomerated, as already 
mentioned above. In general, the results obtained are consentient with the requirements found 
in literature for API PSD (Kaialy et. al.)69. 
The agglomeration of small particles is a regular phenomenon. Particles with higher 
percentage of fine particles tend to be more cohesive. For that reason, smaller particles such 
as API particles will have difficulties to disperse. To avoid the latter, two approaches can be 
employed: (1) controlled aggregation of the undiluted drug in order to obtain loosely adherent 
floccules; (2) mix fine drug particles with coarser carrier particles (approach used in this 
thesis)70. 
Adhesive blends are a formulation strategy for DPIs as  particles can improve some 
of the characteristics of the micronized API. For example, the PSD and the particle surface 
characteristics of the carriers, can be used to influence and control the performance of the fine 
API particles, i.e. improve their flowability, increase dispersion during emission and improve 
dosing40. However, as already explained, only the API has the necessary aerodynamic 
diameter to reach the lungs8,22. 
According to Figure 12(c) with the highest percentage of fine particles, 
-tom_sm. The blend with the lowest percentage of fine particles is 
-tom_lar. When compared to the percentage of fine particles in the raw materials, an 
increased load of fines was seen, which is expected since the blends have 2% of SS. 
Examining carefully, on average, there is an increase of 4.22% of fine particles in SS+ , 
4.05% in SS+ -sph, 4.22% in SS+ -tom_sm and 3.75% in SS+ -tom_lar. 
Interestingly, this value is two times the expected 2% increase when the mentioned API load 
was mixed with the carrier. Thus, it is hypothesized that this might be due to the differences in 
powder bulk volume of the API in relation to the carrier particles; being that, it is expected that 
the micronized particles have a higher powder bulk volume than coarser ones58,71, possibly 
explaining why more than a 2% increase was found. 
Analysing the obtained results with the Span value in Tables 4 and comparing them with 
Figure 12(c), it is conclusive than higher values of Span are related to higher percentage of 
fine particles, since higher values of Span mean that the particle size has a heterodispersed 
distribution and it is notorious that blends have a considerable amount of particles smaller than 
20 . 
As certain amount of fines will undoubtedly help DPI performance, the blends trend as 
> -tom_sm > -tom_lar -sph. Thus, in the next 
sections it will be analysed how the PSD can be correlated or not with powder hardness, 
flowability and in vitro aerodynamic performance. 
 
Finally, to compare all the previous results, lactoses and SS were studied via wet dispersion, 
as well. Wet dispersion measurement complements dry dispersion analysis, by giving a clearer 
understanding when breakage/dispersion of agglomerates/particles occurs. That is, dispersion 
forces in wet dispersion are not so high and can offer an idea about the un-dispersed powder 
system72. In Figures 13 and 14 it is possible to see the Dv0.5 results obtained by dry and wet 
dispersion to raw materials and blends, respectively. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13  Mean particle size values obtained via dry dispersion at primary titration of 0.1, 
1.5 and 2.0 bar and mean particle size obtained via wet dispersion for (a) L , (b) LH -sph, 
(c) LH -tom_sm, (d) LH -tom_lar and (e) SS  
Triplicates were carried out (Mean  
(a) (b) 
(c) (d) 
(e) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 - Mean particle size values obtained via dry dispersion at primary titration of 0.1, 
1.5 and 2.0 bar and mean particle size obtained via wet dispersion for (a) SS+L , (b) 
SS+LH -sph, (c) SS+LH -tom_sm and (d) SS+LH -tom_lar  
Triplicates were carried out  
 
Comparing the results of Dv0.5 obtained by dry and wet dispersion, it is possible to withdraw 
some conclusions. Whenever the Dv0.5 value obtained through wet dispersion were higher than 
dry dispersion ones, it indicated that the powders were composed of aggregates larger than 
single particles, being , seen in Figure 13(a) (Dv0.5  
Dv0.5_1.5bar =  0.5  0.5  
. This interpretation was supported by SEM images (section 3.1.2.) that indicated this was 
the In the other three lactoses, Dv0.5 values obtained by dry dispersion were lower 
or very similar to those obtained when the study was carried out in a wet dispersion mode, 
indicating that particle aggregates were not so prevalent. Moreover, API results supported the 
hypothesis that aggregates are not efficiently dispersed during wet-dispersion and that SS 
particles tendentially form large aggregates. 
(a) (b) 
(c) (d) 
As already mentioned, SS particles (Figure 13(e)) tend to form large aggregates. These 
cohesive interactions, lead to agglomerated samples with a  high surface energy and thus 
difficult to disperse40,73,74. As such, the addition of fine excipients can help buffer drug-drug 
interactions, avoiding the formation of strong API agglomerates that, otherwise, would have a 
detrimental effect on powder processability (i.e. mixing, capsule filling, aerodynamic 
performance)74. 
Regarding the blends (Figure 14), it is possible to see that the agglomerates are not 
breaking, which leads to bigger particles when the blends are studied. This can be explained 
by the fact that these blends have SS and, as already mentioned, micronized particles tend to 
be more cohesive and agglomerate with each other74. As seen before, the values obtained for 
SS by wet dispersion are extremely high, which can mean that the particles are not dispersing 
or not breaking. However, in this case, since the blends are homogeneous, these higher values 
found in wet-dispersion measurement can be explained by the fact that API particles are 
attached to the  surface. 
 
4.1.3. Hardness and Tensile Strength 
The relation between the hardness and TS is proportional. The values of the hardness were 
obtained directly using a 3-in-1 hardness, diameter and thickness testing instrument (Table 5) 
and its representation can be found in Figure 15. 
 
Table 5  Hardness, thickness and diameter of the produced plugs using the raw materials 
and blends.  
Material Thickness (mm) Hardness (N) 
   
-sph   
-tom_sm   
-tom_lar   
SS   
   
-sph   
-tom_sm   
-tom_lar   
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Figure 15  Tensile strength (N/m2) of (a) carriers, API and (b) Blends  
5 replicates were carried out (Mean  
 
Conforming to Figure 15(a), LH -sph is the lactose with the highest value of TS 
(TS=312230.24 21125.13 N/m2), while LH -tom_sm (TS=87382.51 18925.24 N/m2) and 
LH -tom_lar (TS=65956.00 9112.71 N/m2) have the lowest values. Ranking all the raw 
materials results that SS > LH -sph >  LH -tom_sm > LH -tom_lar. 
In terms of particle shape, it is possible to say that spherical particles have a minor tendency 
to deform/break, because they compact in a more cohesive way38, which leads to a higher 
value of TS for LH -sph. Non-regular particles, which is the case of , LH -tom_sm and LH -
tom_lar, tend to deform/break more easily. Besides particle shape, also particle size and the 
percentage of fines have a central importance in the obtained results. When analysing the SS 
result, it is evident that is the raw material with the highest value of TS and this result from the 
fact that SS has a greater percentage of fine particles. Also, although these particles have the 
(a) 
(b) 
same particle shape, there is a small difference between the TS obtained for LH -tom_sm and 
LH -tom_lar, in which the first one has the higher value. This result is due to the percentage 
of fines present in each of the lactose particles: LH -tom_sm has the highest percentage of 
fine particles when compared with LH -tom_lar (2.95%, on average, according to Figure 12(a)) 
and, naturally, has a higher TS associated. 
According to the fluidization theory, a bigger percentage of fines lead to a higher TS, which 
is directly related to the interparticulate forces and the free volume of the carrier: the greater 
the interparticulate forces, the higher the TS71. It is also known that powder flowability, packing 
properties and tensile strength have a drastic effect on powder fluidization and, consequently, 
in aerodynamic performance, increasing the aerodynamic drag force applied to fluidize the 
powder bed. 
In the case of the blends, represented in Figure 15(b), it is possible to rank them: SS+ -
-tom_sm > SS+LH -tom_lar, which is the expected ranking, 
considering the results for the raw materials used in these blends. Likewise, the values of TS 
are now higher, which is expected as well. It is proposed that this occurs due to the exposure 
of smaller drug particles at the carrier surface, leading to the creation of solid bridges, resulting 
in a more compact agglomerate, which results in higher values of hardness/TS75. Moreover, 
when there is a higher percentage of fine particles, it is expected that more contact points exist 
and when the powder was compressed, a plastic deformation led to an increase of the contact 
surface area between API and carrier particles, increasing the adhesion force76. 
 
4.1.4. Density and Porosity 
Since the TS was measured, understanding what was happening with porosity was an 
essential parameter to analyse. The results are represented in Figure 16. 
Ranking the raw materials in terms of porosity, results that LH -tom_sm -tom_lar 
-sph > SS. Therefore, it seems to exist a relation between the hardness/TS and the 
porosity: higher values of hardness correspond to lower value of porosity, in general. As 
described in the literature, TS is a function of the cohesive forces at the contact points and an 
inverse function of both particle diameter and its porosity38. It is visible, in Figure 16(a), that 
-sph presented the lowest value of porosity among the lactoses and this happened due to 
the fact that it has a spherical shape. This lead to a more organized disposition of the particles, 
presenting uniform packing arrangement with higher powder bed TS, which reduces the 
porosity of the powder63. 
Badawy et.al.77 have demonstrated that particle size of the carriers is related with the 
porosity as well: when the carrier particles are smaller, its porosity tends to be higher since 
they showed a reduced tendency for densification. Increasing the particle size, a less porous 
powder is obtained because there is a decrease in both capillarity and viscous interparticle 
forces which leads to a more deformable particle. According to Figure 16(a), it is possible to 
see a relation between the smaller particle size and the higher value of porosity. However, 
concerning the API, this principle cannot be applied, since SS is the raw material with the 
smallest particles, being micronized and compacting better. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16  Porosity, in percentage, of the (a) carriers, API and (b) produced blends 
 
 
Concerning the blends represented in Figure 16(b), the porosity values are not inversely 
proportional to those obtained for the hardness, at least regarding the SS+ -sph, contrary 
to what was initially expected. In this case, SS+ -sph has the highest value of porosity, 
although being expected to have the lowest value of all the blends, and the remaining blends 
have now a slightly lower value of porosity. Considering the literature, after the exposure of the 
lactose to fine particles, solid bridges between both materials are formed, resulting in a more 
(b) 
(a) 
compact and less porous agglomerate75, as already explained before. This was the case in 
SS+ , SS+ -tom_sm and -tom_lar. 
According to Zeng et. al.38, compressing a powder can create several artefacts since 
compression may alter some of the intrinsic properties of the materials and this could be the 
reason why -sph results are different from what was expected. Moreover, SS can also 
alter the properties of the lactoses, namely their porosity. To be sure about what is changing, 
further studies are required. For example, SEM images of the compacted blends can elucidate 
about the presence of any particle changes after compression. Compression might have 
changed the shape of the carrier, causing a change in its porosity, i.e. when compressed at a 
specific pressure, the particles may have changed their shape in the presence of SS, to a 
smaller value of bulk density, smaller tap density and higher porosity78. 
 
4.1.5. Compressibility, Permeability and Cohesivity 
Compressibility 
The powder bulk properties were also analysed in order to understand how powder 
properties influence these results. First, a compressibility test was conducted, and the results 
are represented in Figure 17. 
 is the lactose with the highest value of compressibility and SS has the highest value of 
compressibility of all the powders studied. The percentage change in volume after 
compression (CPS) tends to increase with the increase of the applied pressure. The behaviour 
of powders under compression can be used as a generic criterion for powder flowability. 
Cohesive powders have an aleatory packing and compress easily, which means they have 
poor flowability71. As already mentioned, a higher percentage of fine particles in a powder turns 
the powder more cohesive70 and, actually, it is possible to see that the raw materials with higher 
percentage of fines, which correspond to the ones with higher value of Span, are those that 
have a higher value of compressibility. It is also reported in the literature that the presence of 
fine particles increases the cohesive interparticulate forces inside the powder bed and affects 
the TS, increasing it as well. When an increasing consolidation stress is applied to the powder, 
the TS of a cohesive material will increase, impacting on fluidization and overall performance 
of DPI formulation71. 
The surface geometry and the physical behaviour of the granules influence the 
compressibility results. Surface roughness, for instance, can largely explain these results; that 
is, a rougher surface leads to a greater value of compressibility38. Analysing the values of the 
ghest value 
of SSA, which supports the former. 
 
 
  
 
 
 
 
Figure 17  Percentage change in volume after compression for (a) carriers, API and (b) 
blends at different pressures applied from 1 to 15 kPa 
Triplicates were carried out (Mean  
 
Since one of the ways to decrease the cohesion and, consequently, the agglomeration of 
fine cohesive particles, is to blend coarse lactose carriers with API, the compressibility was 
also tested for the blends. According to Figure 17(b), it is evident that SS+  has the highest 
value of compressibility and that SS+ - -tom_lar are the blends with the 
lowest values. Although the ranking of compressibility is the same as that for the raw materials, 
it was -tom_sm had a greater effect than in the other 
lactoses. -tom_sm has a small SSA, relatively high percentage of fines and a 
wide PSD, as it is possible to confirm in the previous tests. -tom_sm 
(a) 
(b) 
has less space available to SS to adhere to its surface, which means these particles of API will 
be closer to each other, increasing the cohesivity of the blend38,71. 
According to Santl et. al.79, wider PSD contribute to a denser packing of the particles, 
leading to higher values of compressibility. As seen before, higher values of Span mean wider 
, as expected, have the higher values 
of compressibility as well. Thus, considering this theory, it was -sph 
would have the second higher value of compressibility. However, this was not verified since in 
materials with high tendency to fragment (such as the spherical particles), the original particle 
size is less important than for plastic or non-fragmenting materials79. 
 
Permeability 
The permeability of the powders was tested as well, in order to understand the effect of the 
bulk powder properties on the fluidization properties. This measure demonstrates how easily 
the material can transmit a fluid, air in this specific case, through its bulk. The process is very 
similar to the compressibility, but in this case a quantity of air goes through the sample during 
the compression (Figure 18). The results represented below are in values of Pressure Drop 
(PD) and not in permeability itself. So, it is important to consider that PD and permeability have 
an inverse relation; in other words, when the value of PD increases, the value of permeability 
decreases.  
as the lowest values of 
pe
between particles. Therefore it is enlightening that the smaller the particle size, the smaller the 
permeability of the powder, resulting in an inverse proportionality between compressibility and 
permeability71 -tom_lar, being the lactose with the biggest particles, has the highest values 
of permeability (lowest values of PD). According to Cordts and Steckel80, the values for the PD 
across the powder bed can be correlated to the overall fine content, so the more fines found 
in the sample, the smaller the permeability value at a given applied normal stress. With the 
increase of the compression, the empty spaces between the particles will become smaller and 
smaller, leading to an increase in resistance to air throughput. Hence, the behaviour seen for 
SS can be explained by this and, as a result, the air is not free to permeate through the powder 
bed and the airflow permeate through channels formed within the powder bed71. 
Moreover, according to Shalash et. al.81, in addition to the percentage of fines, the 
permeability of the powder bed is also associated to PDS, shape, porosity, cohesivity, 
compressibility and TS. As represented in Table 3, SS is the raw material with higher value of 
lower permeability and a higher compressibility and cohesivity, since they have also a higher 
percentage of fine particles, turning the material more cohesive. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18  Pressure drop variation for (a) carriers, API and (b) blends at different pressures 
applied from 1 to 15 kPa, with a constant airflow velocity of 2 mm.s-1 
Triplicates were carried out (Mean  
 
Naturally, as seen in Figure 18(b),  the blend with the lowest value of permeability. 
-tom_lar, where a blend with the largest particles was produced, the highest values of 
permeability were found. So, it is possible to say as well that the ranking of permeability 
remains the same in Figure 18(b). Cordts and Steckel80 supported these results, where the 
authors related the percentage of existing fine particles with the PD value, which means that 
the higher the amount of fines, the lower the permeability.  
Studies about the relationship between the permeability and the DPI performance have 
shown that performance improves when the permeability of the carrier or the inhalation mixture 
decreases. However, for turbulent-shear inhalers, there are some authors that find this 
(a) 
(b) 
relationship very complex81. According to one of the theories to explain the relation between 
the amount of fine particles and the aerodynamic performance of DPI is said that fluidization 
of a DPI occurs when the PD across the powder bed is equivalent to the weight of the powder. 
So, the addition of fines improves DPI performance by increasing the TS of the formulations, 
which is related to the interparticulate forces and the free volume of the carrier. This means 
than when the permeability of the blend is lower, there is a higher amount of fines associated 
to that blend and it presents a better aerodynamic performance, which is expected to be the 
case for  
 
Cohesivity 
In order to investigate the tendency that each material/blend has for interparticle 
interactions, a shear cell test was conducted, and the results are represented in Figure 19. 
The lactose , according to what is represented in 
Figure 19(a). Thus, it can be said that there is a direct proportionality relation between 
compressibility and cohesivity, which also indicates a correlation with the particle size of the 
powders studied. Hence, it is possible to say that smaller particles tend to have higher values 
of cohesivity, having a higher interparticulate force, which explains why SS has the highest 
-sph 
is the l - -
-sph. According to Kou et.al.82, roughness and morphology are a key aspect to 
understand the cohesion of the materials. If the material is rough, the cohesion is higher and 
if the -sph is the least 
cohesive material, since it is rough but spherical. Also, it is known that spherical particles have 
a higher flowability when compared with irregular particles, due to less interparticle contact 
points31,58, which reduces the aerodynamic performance of DPIs31. Also, it is visible that the 
- -tom_lar, since they just 
differ in their size and, for this specific parameter, size is not as relevant as roughness and 
morphology. 
Considering Figure 19(b), the ranking of cohesivity is the same as Figure 19(a), which 
-sph has the 
lowest values of all the four blends. Although, blends have higher cohesivity values. According 
to Leuenberg et. al.83, the cohesion between fine drug particles and coarse carrier particles 
increase and the interactive forces, such as the Van der Waals attractive force between the 
mixed powder particles increase. This increase influences the aerodynamic performance of 
DPIs, improving the performance, since Van der Waals forces are very weak and allow the 
API to detach more easily from the coarse carrier. Furthermore, it is visible that smaller and 
more irregular particles have higher values of cohesivity and the spherical ones are those with 
less cohesivity, which is concordant with the results found in literature82. Irregular and smaller 
particles during the mixing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19  Supersonic shear imaging for (a) carriers, API and (b) blends at different 
pressures applied from 5 to 15 kPa  
Triplicates were carried out (Mean  
 
It was confirmed that a higher percentage of fines can increase compressibility, decreasing 
the air permeability of the powder bed. The effect of fines leads to a better aerodynamic 
performance of DPIs71, which means that materials that compress better have better results in 
aerodynamic performance, as well. 
 
 
(a) 
(b) 
4.1.6. Aerosolization Performance 
After the evaluation of the particle characteristics and bulk properties, in vitro aerosolization 
performance was performed. As already mentioned in section 1.4.3.2., this in vitro test allows 
the determination of the in vivo action of the formulation, simulating the aerosol deposition into 
the lungs61. 
It is known that several properties influence the aerodynamic performance of DPIs, such as 
the percentage of fine particles, permeability and compressibility of the materials used in the 
formulation, shape of the particles, etc.40,80,84. Which was important to know now was to 
understand which property most influence these results. For that, API particles were separated 
according to their cut-off diameters, as represented in Table 6.  
 
Table 6  Cut-off diameters of the individual stages at 60 and 100 L/min 
Stages 60 L/min 100 L/min 
S1 6.12 8.06 
S2 3.42 4.46 
S3 2.18 2.82 
S4 1.31 1.66 
S5 0.72 0.94 
S6 0.40 0.55 
S7 0.24 0.34 
S8 <0.24 <0.34 
 
Table 7, represented below, include the parameters describing the aerodynamic 
performance of the four blends at both flow-rates. The emitted dose (ED) represents the 
quantity of powder that came out of the device and capsules, its correspondent value in relation 
to the total dose of API  the emitted dose of the dose (EDD), the FPF and its correspondent 
value in mass (FPD), as well as the MMDA were calculated in accordance to the US 
Pharmacopeia.  
For all the blends studied, the results concerning the EDD were very similar, being these 
between 82-105%, meaning that no notable differences were found regarding this parameter 
between both flow- -sph, presented an EDD below 
the total amount of SS in the blends, which implied that a certain quantity of SS remained in 
the capsules and/or in the inhalation device. It is known that large intra- and inter-inhaler dose 
emission differences may result in asthma and COPD exacerbations and this may also occur 
due to the absence of immediate therapeutic feedback during inhalation84. So, it is very 
important that the EDD value are still the same regardless the flow-rate used, since not all the 
patients are able to achieve the same flow-rate values during inhalation. 
 
Table 7  Aerodynamic performance results (ED, EDD, FPD, FPF and MMAD values) of the 
four blends at 60 and 100 L/min 
Blends  EDD (%)  FPF (%)  
60 L/min 
SS+       
SS+ -sph      
SS+ -
tom_sm 
  757.92    
SS+ -
tom_lar 
     
100 L/min 
      
-sph    1.60  
-
tom_sm 
     
-
tom_lar 
     
 
 
Besides the EDD, the main parameter that affects the DPI efficacy is the FPF. In general, it 
is possible to see that a flow-rate of 100 L/min led to higher values of FPF
-tom_sm almost no difference could be found between the used flow-rates. Since 
not every patient is able to achieve the same flow-rate during inhalation and, as said before, 
the same amount of API should reach the lungs regardless the inhalation capacity of each 
person  -tom_sm could be 
advantageous for DPI performance. It was also evident that blends with higher values of fine 
particles had the best results concerning FPF, which according to the literature was to be 
expected. According to Grasmeijer et. al.85 and Guenette et. al.67, a constant positive 
relationship exists between fine lactose content of different blends and the FPF of SS for cut-
 It is well-known that fine particles improve the performance of 
DPIs, however the reason why this is so is still under discussion (section 1.4.2.2.1.). For 
example, one of the theories says that the carrier has areas which are more adhesive than 
others and they are occupied by fines, leaving the less energetic spots to API fines, which 
leads to an easier detachment from the carrier surface40. In turn -sph blends had the 
lowest FPF. It is spe -sph blends form powder beds that break as plugs or 
fractures instead of an aerosol cloud, as such the API cannot reach the lungs. It is known that 
spherical particles tend to be more cohesive, having a uniform packing arrangement with 
higher TS (as demonstrated in section 4.1.3.). These type of particles is difficult to fluidize via 
airflow, resulting in an inferior and variable lung deposition of fine particles63. Moreover, the big 
pores and roughness at the surface of the carrier might have provided shelter for the API 
particles to be shield against fluidization forces63. Thus, it was no surprise that this carrier 
showed a markedly worst aerodynamic performance. 
According to Table 7, - -
tom_lar it was also possible to conclude that particles of the same shape and similar roughness 
led to worse results of aerodynamic performance. A possible explanation for the former is that 
larger carrier particles exhibit higher press-on forces during mixing with micronized API, due 
to their larger mass and inertia, resulting in stronger adhesive forces86. In addition, lactose 
powders with irregular shape and rough surface are expected to have lower Van der Waals 
interparticulate forces, dispersing better upon aerosolization87. Furthermore, blends of API with 
these type of lactose powders are expected to have a higher porosity, lower permeability and 
higher cohesivity, as well as compressibility. Therefore, these confirmed the hypothesis 
proposed in section 4.1.5. and a better aerodynamic performance were seen in the case of 
-tom_sm). 
Another important parameter to consider after aerodynamic analysis is the MMAD. Larger 
values of MMAD are expected for aerosolizing blends where drug agglomerates are present63. 
Thus, naturally, MMAD values differ regarding the flow-rate used. In line with the fracture 
hypothesis proposed above, at 100 L/min -sph was the blend with larger MMAD, 
resulting in the smallest value of FPF among the tested blends.  
had the highest value of MMAD, which was not expected. Hence, further research is needed 
in order to understand more in-depth how the flow-rate affected the MMAD. -sph has a 
regular shape (spherical) and a rough surface, since has deep gaps and large pores and this 
structure contributed to the aerosolization performance63.  
 
In Figure 20 it is possible to confirm what was said when analysing the previous tables. 
These plots illustrate the deposition of SS particles in the different stages of the impactor for a 
flow-rate of 60 L/min and 100 L/min. 
It was evident that most of the SS particles impacted in the pre-separator. This might be 
explained by the fact that a high percentage of those particles were attached more tightly to 
the carrier surface and as such, not able to detach during inhalation. Consequently, these high 
SS content in the pre-separator led to not even 50% of the drug being able to reach the lower 
stages of the NGI. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 - Amount of SS (w%) deposited on the inhaler device + capsules shells, 
mouthpiece+throat, pre-separator and different stages after aerosolization of the DPI blends, 
operating at a flow-rate of (a) 60 L/min and (b) 100L/min 
Triplicates were carried out (Mean  
 
 
(a) 
(b) 
For both flow-rates it was visible a superior and constant in vitro aerosolization performance 
greater percentage of fine particles, lower permeability and higher compressibility and 
cohesivity values, leading to a better detachment of API particles from the carrier88.  
Therefore, considering all the results obtained, it is possible to say that the percentage of 
fine particles is the property which contributes the most to a better aerodynamic performance 
of DPIs. However, the former is not the only property that should be considered when deciding 
which carrier to be used in a DPI formulation, in order to obtain a good performance. As an 
example, a bigger percentage of fines lead to a higher TS, which is related to the 
interparticulate forces and the free volume of the carrier: the greater the interparticulate forces, 
the higher the TS71. Also, powder flowability and packing properties are influenced by the 
percentage of fines, having a drastic effect on powder fluidization and, consequently, in 
aerodynamic performance, which can be confirmed by analysing Table 7 and Figures 20 (a) 
and (b). 
 
 
 
  
5. CONCLUSION 
The present work confirmed that different particle characteristics, such as particle size, 
shape and morphology, produced powder beds with distinct adhesive and cohesive properties, 
affecting the flowability, compressibility and permeability of the produced blends. Moreover, in 
vitro testing using an NGI elucidated how particle and powder bulk properties can influence 
the aerodynamic performance. It was hereby confirmed the importance of particle size, shape 
and percentage of fines, showing how carrier particles can be engineered to improve DPI 
performance. 
After confirming that all the produced blends exhibited the intended mixing homogeneities, 
they were used for further in vitro testing. Powder bulk characterization displayed that different 
blends have different behaviours in terms of compressibility, permeability and cohesivity, 
showing that the characteristics of the powders influence these powder bulk properties. For 
instance, the best blend studied, presenting the best aerodynamic performance, was SS+ . 
This presented higher compressibility and cohesivity, as well as lower permeability. The former 
was shown to be dependent of the particle size of the carrier, as well as its shape.  
Also, the TS and porosity were studied showing the expected results: spherical particles, 
which is the case of the -sph, had a higher value of TS, when comparing with more non-
regular particles. Between TS and porosity an inverse relationship was found, which means 
that -sph was the least porous lactose studied. However, this relation was not verified 
when the blend was analysed and, for that reason, further investigations are required.  
Two different flow-rates were tested, 60L/min and 100L/min, to understand how the aerosol 
deposit in the lugs. The best results were obtained for SS+ . The superior aerodynamic 
performance of this blend could be justified by its higher percentage of fine particles, as well 
as the non-regular shape of , possibly leading to easier API detachment during 
aerosolization. Additionally, FPF, ED values, as well as SS content in the different stages were 
constant regardless of the flow-rate used. This reveals the advantage of using carriers with 
, since the delivered dose of API should be the same regardless the 
flow-rate generated by the patient. The worst aerodynamic performance was obtained for 
SS+ -sph. The spherical morphology of this carrier and correspondent higher TS, as well 
as its big pores and gaps at the surface made fluidization difficult and enabled the small API 
particles to be sheltered against aerosolization forces, respectively.  
Taking into account all the findings and confirmations in the present work, it can be stated 
that a higher percentage of fine particles is a critical parameter to consider for capsule based 
DPI devices, since it influences all of the properties studied and leads to a better aerodynamic 
performance. Thus, it is also proposed that a carrier with similar properties to the ones found 
d DPI formulations. 
Therefore, it is possible to confirm the hypothesis initially established in this thesis. 
 
  
6. FUTURE PERSPECTIVES 
Some aspects of this work need further investigations to understand clearly some important 
results. 
-sph was not expected. In order to 
understand this inconsistency, morphology and surface tests should be conducted. 
Alternatively, plugs should be produced using different pressures to understand if there is a 
point beyond which the characteristics of the powder actually change. 
As the -sph, it was 
presumed that the spherical morphology of this carrier and correspondent higher TS, as well 
as its big pores and gaps at the surface, made fluidization difficult and enabled the small API 
particles to be sheltered against aerosolization forces. However, further research is needed to 
prove these statements, i.e. SEM images after NGI performance. 
Also, in order to obtain more precise results concerning the TS and porosity, the bulk density 
of the materials should be measured instead of calculated. 
Moreover, to be sure about the contributions of all particle and bulk properties in DPI 
performance, a multivariate analysis should be conducted. 
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